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j ourna l homepage: www.e lsev ie r .com/ locate /atgEditorialSpecial Issue — From Biobanks to the Clinic“This is a time of dramatic change in medicine. As we cross the
threshold of the new millennium, we simultaneously cross a
threshold into an era where the human genome sequence is largely
known.Wemust commit ourselves to exploring application of these
powerful tools to the alleviation of human suffering, a mandate that
undergirds all of medicine.”
[-Francis S. Collins & Victor A. McKusick, 2001]
In 2009, Time Magazine identiﬁed biobanks as one of the ten ideas
changing the world (Parks, 2009). These organized collections of
human biological samples and associated data are “vital research tools
in the drive to uncover the consequences of human health and disease”
(Chalmers and Nicol, 2008). Today, with many of these infrastructures
gradually achieving their recruitment objectives, current initiatives are
focusing on the orderly translation of research knowledge into beneﬁ-
cial clinical applications. Indeed, whether it is through international
collaboration aimed at increasing statistical power (Burton et al.,
2009), or broader access to comprehensive data meant to better under-
stand the role of human genomic variation in “complex disease
aetiology and treatment” (Knoppers et al., 2011), biobank researchers
wish to realize the full beneﬁts for which participants have provided
their data and samples.
This Special Issue “FromBiobanks to the Clinic” examines theways in
which biobanks are facilitating this translation. In Rare Disease
Research: Breaking the Privacy Barrier, Mascalzoni, Paradiso andHansson
discuss the effects of privacy on rare disease research and biobanking.
Although the aggregation of health-related data has become a pressing
need in these projects, the collection and use of large quantities of
health information create challenges for patient privacy. The authors
highlight some of these challenges, including the problem of speciﬁc
informed consent procedures. They explain that genomics should also
focus on the beneﬁts for society as a whole. In order to improve
researcher–patient relationships, researchers could consider patients
as partners, and acknowledge them as valuable contributors to genetic
research. In this way, the authors hope that biobanks will foster transla-
tional practices, while protecting individual rights.
In turn, Brankovic, Malogajski and Morré discuss biobanking in the
context of infectious disease research, using HIV, Chlamydia and
Human Papillomavirus as case studies. Through an examination of
various biobank consortia, including the Infectious Diseases Biobank at
King's College London and the Spanish HIV Biobank, the authors dem-
onstrate how biobanks have successfully contributed to the translation
of research data to clinics and patients. In each case study, the authors
were able to demonstrate how biobank genomic research data can
lead to a better understanding of infectious diseases in the clinical set-
ting; for example, the translation of HPV research results is contributinghttp://dx.doi.org/10.1016/j.atg.2014.04.002
2212-0661/© 2014 The Authors. Published by Elsevier B.V. This is an open access article underto better diagnostics of cervical cancer and its intermittent stages. The
authors also stress the importance of electronic health records in
providing access to a more comprehensive set of data; vital for the
future utilization of biobanks.
In P3G — 10 Years of Toolbuilding: From the Population Biobank to the
Clinic, Ouellette and Tassé discuss the evolution of the Public Population
Project in Genomics and Society (P3G), a non-proﬁt international
consortium focusing on genomics and biobanking. From its inception,
P3G has sought to develop tools for the conceptualization of biobanks,
and has become key in fostering infrastructure research to facilitate
the translation of biobank knowledge to clinical use. Biobank tools, sup-
port systems and networks help the international research community
use health and social data for healthcare strategies aimed at disease
prevention and tailored treatments. P3G's comprehensive website
describes its research programmes and also includes a TOOLKIT for
epidemiological, ethical, statistical and IT tools for the access and use
of biobanks, while its CATALOGUES provide easy access to information
about large population-based biobanks.
In brief, the articles in this Special Issue cover a broad spectrum of
critical issues and tools facilitating the clinical uptake of biobank
research. Written by an international group of scientists, ethicists and
jurists, they are a reﬂection of current efforts aimed at fostering the
orderly translation of knowledge from the bench to the bedside. For
biobanks, continuing on this path will not only ensure better healthcare
planning for the health systems that will serve future generations, but
hopefully also strengthen and sustain public trust for many years to
come.
What this Special Issue illustrates above all, is the tension between
“old” and “new” science and ethics since the launching of the Human
Genome Project in the 1990s. The old, epitomized by the single “genius”
researcher, is now giving way to international consortia with collabora-
tive data sharing. The emphasis on personal autonomy andprivacy at all
costs, especially as concerns genetic research, is now giving way to
broad consent for biobanks (populational or rare disease) serving as
resources, that is, as infrastructures for speciﬁc disease research.
The challenge for the next quarter century will be the sustainability
of these biobank infrastructures for their clinical use in healthcare
systems.
As a research participant, the modern citizen contributes to the
solidarity ethos of research that creates generalizable knowledge for
the public good; as a patient, however, choices as concern intervention-
ism, clinical trials or medical care are intensely personal. Confusing the
role of the quality and social needs of research and the need for individ-
ual choice inmedical care can undermine the global need for research to
scientiﬁcally underpinmedical care. Biobanks and data sharing are a so-
cial enterprise that can and should undergird as well as sustain the
viability of quality healthcare for all, including – as we have seen –the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
22 Editorialthosewith rare diseases and infectious diseases. Personal expressions of
choice as concerns donating to infrastructure biobanks can always be
expressed by non-participation (i.e. opt-out). Adding the slippery
slope of multiple individual choice to such participation can only harm
the quality of these biobanks that beneﬁt all science without selection
bias. Multiple consent options should remain in the context of clinical
research and medical care.
Moreover, as the needs of the rare disease and infectious disease
(public health) communities have demonstrated, there is now an even
greater need to support the solidarity “citizen-like” nature of biobanks,
built as they are on public trust, ongoing oversight and transparency.
This contribution of citizens, especially as regards their conﬁdence in
the ethical governance of biobanks and in the international sharing of
their data and samples, is distinct from the need to provide consent
choices in either clinical research involving interventions or in personal
medical care. The contents of this Special Issue are illustrative of these
scientiﬁc policies, and, personal challenges. Note the words of caution
of the legal scholars at the Mason Institute:
We do not support a dynamic consent approach on both principled
and pragmatic grounds. First, as a matter of principle this re-
enforces a highly individualistic (property-like) approach to data
and its control which is likely to compromise solidarity interests in
data uses for a range of purposes that can beneﬁt both individual
and public interests. Pragmatically, we question whether this is
the best use of ﬁnite research resources to have to design such
mechanisms when this will necessarily be at the expense of other
research-focused expenditure (Laurie et al., 2013).
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